- Argentina
- Australia
- Austria
- Bangladesh
- Belgium
- Botswana
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Cuba
- Czech Republic
- Egypt
- Estonia
- Ethiopia
- Finland
- France
- Germany
- Ghana
- Greece
- Hong Kong
- Hungary
- India
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Kenya
- Latvia
- Lebanon
- Lithuania
- Malaysia
- Mexico
- Morocco
- Namibia
- Netherlands
- New Zealand
- Nigeria
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Romania
- Russia
- Saudi Arabia
- Senegal
- Singapore
- Slovakia
- Slovenia
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Tanzania
- Thailand
- Turkey
- Uganda
- Ukraine
- United Arab Emirates
- United Kingdom
- United States
- Venezuela
- Vietnam
- Zimbabwe
China Business News API
Get the live top business headlines from China with our JSON API.
Get API key for the China Business News APIAPI Demonstration
This example demonstrates the HTTP request to make and the JSON response you will receive when you use the news api to get the top headlines from China.
GET
https://gnews.io/api/v4/top-headlines?country=cn&category=business&apikey=API_KEY
{
"totalArticles": 116524,
"articles": [
{
"id": "e0cc3151c48a20f965ed45e5aaf2dc47",
"title": "5月新势力排位生变:零跑破8万辆、鸿蒙回升、蔚来逼近4万辆",
"description": "3万辆成门槛,8万辆破上限。",
"content": "21世纪经济报道记者 郑植文\n2026年的中国车市,价格战仍未结束,智能化竞赛持续加速。过去几年靠一个爆款、一场发布会、一个技术标签就能迅速出圈的阶段,正在过去。今天的新能源车企,比拼的不再只是声量,而是产品密度、成本控制、渠道效率、交付能力和组织韧性组成的体系能力。\n更残酷的是,市场一边在增长,一边也在变得更难赚钱。新能源渗透率不断走高,但车企之间的价格边界被一再击穿;用户选择越来越多,决策周期却越来越长;新车发布越来越密集,单一车型的热度衰减也越来越快。对于新势力而言,过去是“活下来”的问题... [3823 chars]",
"url": "https://www.21jingji.com/article/20260601/herald/1eb81ed05a1d7e71614a9e57a864023b.html",
"image": "https://static.21jingji.com/web_fed/images/qrcode/khd.png",
"publishedAt": "2026-06-01T15:12:00Z",
"lang": "zh",
"source": {
"id": "c5d24189b7285113382261608bbff73c",
"name": "21财经",
"url": "https://www.21jingji.com"
}
},
{
"id": "61856296922eeeee9d20544473b64a2b",
"title": "多家中国创新药企亮相ASCO:康方生物再迎高光,恒瑞91项研究入选_10%公司_澎湃新闻",
"description": "5月29日至6月2日,2026年美国临床肿瘤学会(ASCO)年会在美国芝加哥召开。作为全球肿瘤领域的顶级学术盛会,国内外众多药企的研究成果以全体大会、口头报告专",
"content": "5月29日至6月2日,2026年美国临床肿瘤学会(ASCO)年会在美国芝加哥召开。作为全球肿瘤领域的顶级学术盛会,国内外众多药企的研究成果以全体大会、口头报告专场、壁报等多种形式亮相ASCO。\n在2026年ASCO上,来自康方生物(9926.HK)、恒瑞医药(600276.SH)、翰森制药(3692.HK)、信达生物(1801.HK)等中国本土创新药企的研究数据亮相,展示了中国医药创新的力量。尽管二级市场“不涨反跌”,但业内人士指出,这并不能掩盖中国创新药研发实力正在全面提升的事实。\n中国原创新... [1718 chars]",
"url": "https://www.thepaper.cn/newsDetail_forward_33282041",
"image": "https://www.thepaper.cn/favicon.ico",
"publishedAt": "2026-06-01T14:55:00Z",
"lang": "zh",
"source": {
"id": "3a128398e925e99eda464c693ba9162b",
"name": "thepaper.cn",
"url": "https://www.thepaper.cn"
}
},
{
"id": "4161b9cc749ef85507a68ebd88bce873",
"title": "直击美团业绩会:Q1亏损环比收窄 预期Q2单均利润将改善 “小美”与“元宝”合作将上线",
"description": "《科创板日报》6月1日讯(记者徐赐豪)今日(6月1日),美团公布其最新的财报。财报显示,美团2026年第一季度实现营收910.39亿元,相较于去年同期的862.06亿元同比增加5.6%;经调整的净利润方面,2026年净亏损49.68亿元,而去年同期为净利109.49亿元。",
"content": "《科创板日报》6月1日讯(记者徐赐豪)今日(6月1日),美团公布其最新的财报。\n财报显示,美团2026年第一季度实现营收910.39亿元,相较于去年同期的862.06亿元同比增加5.6%;经调整的净利润方面,2026年净亏损49.68亿元,而去年同期为净利109.49亿元。\n美团CEO王兴在今晚的业绩会上表示,这轮“非理性行业竞争”实际上证明了一点:仅依靠补贴推动的订单增长是不可持续的。真正的长期增长,归根结底是来自供给侧的创新,以及在更多元消费场景下实现需求与供给之间更高效的匹配。\n“利用人工... [2012 chars]",
"url": "https://wap.eastmoney.com/a/202606013756375642.html",
"image": "https://g1.dfcfw.com/g4/202112/20211206191716.png",
"publishedAt": "2026-06-01T14:39:05Z",
"lang": "zh",
"source": {
"id": "5a9da4f0769c682a46311f5a05935d4a",
"name": "东方财富",
"url": "https://wap.eastmoney.com"
}
}
]
}